The global Neuroendocrine Tumors Therapeutics Market is expected to grow at a CAGR of 9.5% during the forecast period 2022 to 2028. Neuroendocrine tumors (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumors can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells whose normal functions are to serve at neuroendocrine interface. Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands. Neuroendocrine tumors therapeutics market expected to grow owing to increase in initiatives taken by various international organizations like American Association for Cancer Research and World Health Organization to treat neuroendocrine tumors are expected to drive the growth of the market. AACR provided $250,000 fund for the Prevention of neuroendocrine tumors. Rise in health care expenditure, increase in prevalence rate of neuroendocrine tumors in developing regions is anticipated to drive global neuroendocrine tumors market. Though the market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restraints for neuroendocrine tumors market.